ArticleBlood transfusion = Trasfusione del sangue2022
Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding.
Article in Blood transfusion = Trasfusione del sangue, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Long-Term Experience with Acquired Haemophilia A: A 40-Year Single-Centre Study of Clinical Features and Outcome.Journal of clinical medicine · 2025Article
- Case Report: Coexisting cold agglutinin disease and acquired hemophilia A: a rituximab-responsive dual autoimmune disorder.Frontiers in medicine · 2025Article
- Real-World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Observational
- Role of the Hemostasis and Thrombosis Unit in the Management of Patients with Acquired Hemophilia ATurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Emicizumab as first-line therapy in acquired hemophilia A.Research and practice in thrombosis and haemostasis · 2024Article
- Successful management of massive postpartum haemorrhage in a woman with acquired haemophilia A.BMJ case reports · 2024Article
- Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS.Therapeutic advances in hematology · 2024Article
- Lupus Anticoagulant Detection under the Magnifying Glass.Journal of clinical medicine · 2023Review
- SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply.Thrombosis research · 2023Article
- Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2023Review
- Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review.Journal of clinical medicine · 2023Article
- Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review.Diagnostics (Basel, Switzerland) · 2022Article
- Analytical Performance of Different Laboratory Methods for Measuring Susoctocog-Alfa.Diagnostics (Basel, Switzerland) · 2022Article
- Acquired Haemophilia A: A Review of What We Know.Journal of blood medicine · 2022Review
- Acquired Haemophilia A and COVID-19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database.Haemophilia : the official journal of the World Federation of HemophiliaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcquired haemophilia A (AHA) is a rare bleeding disorder due to autoantibodies to coagulation factor VIII that may be secondary to autoimmune diseases, cancer, drugs, pregnancy, infections, or be idiopathic. Recurrent bleeding, often severe, mostly in muscles and soft tissues, and isolated prolonged activated partial thromboplastin time (aPTT), in the absence of personal and family history of bleeding, are typical features that should raise the suspicion of AHA. Poor awareness of the disease results in diagnostic delays and inappropriate treatment. MATERIALS AND
methodsThe Italian Association of Haemophilia Centres (AICE) developed consensus recommendations in cooperation with the Italian Society on Thrombosis and Haemostasis (SISET). The document was shared with scientific societies of specialist physicians, laboratory professionals and pharmacists to spread knowledge about AHA and promote appropriate diagnosis/treatment.
resultsReady availability of the aPTT mixing test is crucial, although diagnostic confirmation and optimal management require prompt referral of patients to specialised centres with rapidly available diagnostic and therapeutic facilities. If immediate referral is unfeasible, treatment must be undertaken early, under guidance of specialised centres or based on shared protocols. Recommendations about diagnosis, general management and, in bleeding patients, haemostatic therapy using bypassing agents or replacement treatment, including the recently available recombinant porcine factor VIII, are provided, considering the different clinical settings and laboratory facilities. DISCUSSION: This consensus document aims to improve the overall healthcare pathways for AHA, harmonise the management and therapeutic approaches to newly diagnosed patients and reduce the still relevant complications and mortality in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.